These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 25432773

  • 1. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.
    Bone HG, Dempster DW, Eisman JA, Greenspan SL, McClung MR, Nakamura T, Papapoulos S, Shih WJ, Rybak-Feiglin A, Santora AC, Verbruggen N, Leung AT, Lombardi A.
    Osteoporos Int; 2015 Feb; 26(2):699-712. PubMed ID: 25432773
    [Abstract] [Full Text] [Related]

  • 2. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR, O'Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MS, LOFT Investigators.
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
    [Abstract] [Full Text] [Related]

  • 3. Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis--a double-blind, randomized, dose-finding study.
    Nakamura T, Shiraki M, Fukunaga M, Tomomitsu T, Santora AC, Tsai R, Fujimoto G, Nakagomi M, Tsubouchi H, Rosenberg E, Uchida S.
    Osteoporos Int; 2014 Jan; 25(1):367-76. PubMed ID: 23716037
    [Abstract] [Full Text] [Related]

  • 4. Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial.
    Papapoulos S, Bone H, Cosman F, Dempster DW, McClung MR, Nakamura T, Restrepo JFM, Bouxsein ML, Cohn D, de Papp A, Massaad R, Santora A.
    J Bone Miner Res; 2021 Jul; 36(7):1225-1234. PubMed ID: 33724542
    [Abstract] [Full Text] [Related]

  • 5. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
    Bonnick S, De Villiers T, Odio A, Palacios S, Chapurlat R, DaSilva C, Scott BB, Le Bailly De Tilleghem C, Leung AT, Gurner D.
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
    [Abstract] [Full Text] [Related]

  • 6. Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study.
    Rizzoli R, Benhamou CL, Halse J, Miller PD, Reid IR, Rodríguez Portales JA, DaSilva C, Kroon R, Verbruggen N, Leung AT, Gurner D.
    Osteoporos Int; 2016 Jun; 27(6):2099-107. PubMed ID: 26879200
    [Abstract] [Full Text] [Related]

  • 7. Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis.
    Binkley N, Orwoll E, Chapurlat R, Langdahl BL, Scott BB, Giezek H, Santora AC.
    Osteoporos Int; 2021 Jan; 32(1):173-184. PubMed ID: 33200257
    [Abstract] [Full Text] [Related]

  • 8. Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5-Year Data From the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its Extension.
    Recker R, Dempster D, Langdahl B, Giezek H, Clark S, Ellis G, de Villiers T, Valter I, Zerbini CA, Cohn D, Santora A, Duong LT.
    J Bone Miner Res; 2020 Jul; 35(7):1289-1299. PubMed ID: 32119749
    [Abstract] [Full Text] [Related]

  • 9. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
    Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, Hustad CM, DaSilva C, Santora AC, Ince BA.
    J Bone Miner Res; 2010 May; 25(5):937-47. PubMed ID: 19874198
    [Abstract] [Full Text] [Related]

  • 10. Potential role of odanacatib in the treatment of osteoporosis.
    Ng KW.
    Clin Interv Aging; 2012 May; 7():235-47. PubMed ID: 22866001
    [Abstract] [Full Text] [Related]

  • 11. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
    Brixen K, Chapurlat R, Cheung AM, Keaveny TM, Fuerst T, Engelke K, Recker R, Dardzinski B, Verbruggen N, Ather S, Rosenberg E, de Papp AE.
    J Clin Endocrinol Metab; 2013 Feb; 98(2):571-80. PubMed ID: 23337728
    [Abstract] [Full Text] [Related]

  • 12. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
    Sugimoto T, Matsumoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Fukunaga M, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Okubo N, Shiraki M, Nakamura T.
    Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy.
    Mukherjee K, Chattopadhyay N.
    Biochem Pharmacol; 2016 Oct 01; 117():10-9. PubMed ID: 27106079
    [Abstract] [Full Text] [Related]

  • 14. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.
    Reginster JY, Kaufman JM, Goemaere S, Devogelaer JP, Benhamou CL, Felsenberg D, Diaz-Curiel M, Brandi ML, Badurski J, Wark J, Balogh A, Bruyère O, Roux C.
    Osteoporos Int; 2012 Mar 01; 23(3):1115-22. PubMed ID: 22124575
    [Abstract] [Full Text] [Related]

  • 15. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.
    Meunier PJ, Roux C, Ortolani S, Diaz-Curiel M, Compston J, Marquis P, Cormier C, Isaia G, Badurski J, Wark JD, Collette J, Reginster JY.
    Osteoporos Int; 2009 Oct 01; 20(10):1663-73. PubMed ID: 19153678
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial.
    Binkley N, Bone H, Gilligan JP, Krause DS.
    Osteoporos Int; 2014 Nov 01; 25(11):2649-56. PubMed ID: 25027109
    [Abstract] [Full Text] [Related]

  • 17. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, ACTIVE Study Investigators.
    JAMA; 2016 Aug 16; 316(7):722-33. PubMed ID: 27533157
    [Abstract] [Full Text] [Related]

  • 18. Effects of odanacatib on bone-turnover markers in osteoporotic postmenopausal women: a post hoc analysis of the LOFT study.
    Duong LT, Clark S, Pickarski M, Giezek H, Cohn D, Massaad R, Stoch SA.
    Osteoporos Int; 2022 Oct 16; 33(10):2165-2175. PubMed ID: 35711006
    [Abstract] [Full Text] [Related]

  • 19. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.
    Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjærg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD, Bazedoxifene Study Group.
    Osteoporos Int; 2012 Jan 16; 23(1):351-63. PubMed ID: 21779819
    [Abstract] [Full Text] [Related]

  • 20. Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis.
    Koldkjær Sølling AS, Harsløf T, Langdahl B.
    Osteoporos Int; 2019 May 16; 30(5):995-1002. PubMed ID: 30656367
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.